Deferiprone
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Deferiprone: From Transfusional Iron Overload in Thalassaemia to Hepatic Porphyria
One-Sentence Summary
Deferiprone is an oral iron chelator, originally used to treat iron overload (hemosiderosis) in beta-thalassaemia and related haemoglobin disorders. The TxGNN model predicts it may be effective for hepatic porphyria, but there are 0 registered clinical trials and only 2 publications (one case-level report and one animal study), so the evidence is indirect and preliminary.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hemosiderosis and beta-thalassaemia-related conditions (the Singapore licence entries contain no indication text, so this comes from the knowledge-graph indication list) |
| Predicted New Indication | Hepatic porphyria |
| TxGNN Prediction Score | 99.20% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, deferiprone is an oral iron-selective chelator. Its efficacy in removing iron in transfusional iron overload is established, and mechanistically it may be applicable to porphyrias where iron plays a role.
In porphyria cutanea tarda, excess hepatic iron is thought to worsen porphyrin accumulation by inhibiting uroporphyrinogen decarboxylase. Lowering labile iron could therefore reduce disease activity. Phlebotomy, which also depletes iron, is an effective treatment in this setting.
The supporting studies are indirect. One is a mouse model of porphyria cutanea tarda, and the other is a case-level report in congenital erythropoietic porphyria. Neither is randomised, and the subtypes studied may not match "hepatic porphyria" as a whole.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32678895 | 2020 | Preclinical / case-level study | Blood | Iron chelation rescued haemolytic anaemia and skin photosensitivity in congenital erythropoietic porphyria |
| 17854053 | 2007 | Animal study (mouse) | Hepatology | In Hfe-/- mice with porphyria cutanea tarda, deferiprone was compared with iron-deficient diets as ways to deplete hepatic iron and reduce uroporphyrin accumulation |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13668P | FERRIPROX 100MG/ML ORAL SOLUTION | Solution | Not stated in the data |
| SIN12083P | FERRIPROX FILM-COATED TABLET 500 mg | Film-coated tablet | Not stated in the data |
Safety Considerations
Drug Interactions: The interaction screen found 100 recorded interactions. The entries listed are all rated Moderate. They mainly involve polyvalent metal-containing products, which may bind the chelator:
- Calcium salts (phosphate, acetate, carbonate, citrate, gluconate, lactate, glubionate)
- Magnesium salts (oxide, carbonate, chloride, citrate, gluconate, hydroxide, sulfate)
- Aluminium-containing antacids (aluminium hydroxide, magaldrate)
- Iron, kaolin, attapulgite and sucralfate
Please refer to the package insert for other safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The high TxGNN score is supported only by one mouse study and one case-level report in specific porphyria subtypes, with no registered clinical trials. This is not enough to move toward clinical use, and the package insert safety data are still missing.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA (currently blocking safety screening)
- Mechanism of action data, to support the link between iron chelation and porphyria
- Clarification of which porphyria subtypes are relevant (for example porphyria cutanea tarda versus congenital erythropoietic porphyria)
- Prospective clinical data in humans, such as a pilot study or a systematic review of existing case experience
- A review of the interaction profile and dosing separation from metal-containing products
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.